Skip to Content
U.S. National Institutes of Health
Cancer Diagnosis Program Cancer Imaging Program Cancer Therapy Evaluation Program Developmental Therapeutics Program Radiation Research Program Translational Research Program Biometric Research Branch Office of Cancer Complementary and Alternative Medicine
Last Updated: 04/25/2012


Solicitation of Validated Hits for the Discovery of in vivo Chemical Probes (R01)


Expiration date: September 8, 2014

Contact: Suzanne Forry-Schaudies, Ph.D.
(301) 435-9147,

The NCI is particularly interested in validated hits for targets that address unmet needs in the prevention, treatment, or diagnosis of cancer. Strategies that include testing of in vivo chemical probe activity in primary human tumor cells are encouraged. In vivo chemical probes may be appropriate for entry in the NCI Experimental Therapeutics (NExT) Program for further development to clinical candidate status and testing in clinical trials. See for the NExT application process. Applicants may also find the NCI Developmental Therapeutics Program ( ) resources to be helpful.